Quiet on the insider front: nobody at Moleculin Biotech, Inc. bought or sold MBRX shares at market prices this past year.
No open-market insider buying or selling in the last full quarter. Insiders bought in 1 of the last 7 full quarters. 18 investment managers listed MBRX in their latest 13F filings (Q2 2026); more funds bought than sold.
| Filed | Insider | Role | Type | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Jun 23, 2025 | Foster Jonathan P. | CFO | Buy | 270,270 | $0.37 | $100K | SEC |
| Jun 23, 2025 | KLEMP WALTER V | CEO | Buy | 675,675 | $0.37 | $250K | SEC |
| Dec 27, 2023 | Foster Jonathan P. | CFO | Buy | 28,986 | $0.69 | $20K | SEC |
| Dec 27, 2023 | George Robert E. | Director | Buy | 14,493 | $0.69 | $10K | SEC |
| Dec 27, 2023 | KLEMP WALTER V | CEO | Buy | 188,404 | $0.69 | $130K | SEC |
There were no open-market insider trades in MBRX in the last 12 months. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
18 investment managers reported holding MBRX in SEC Form 13F filings for Q2 2026.
No congressional trades in MBRX were reported in the past two years. The full list is free on CapitalSnitch.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1). Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).